content_top
43 companies, 1 interpreter! Insight, foresight
and recommendation 

Fate Therapeutics, Inc. (FATE)

4.23
0.11
(2.67%)
 Sep 11, 4:00PM EDT
content_middle

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops pharmacologic modulators of adult stem cells to treat orphan diseases. Its hematopoietic stem cell (HSC) modulation platform focuses on the ex vivo pharmacologic optimization of hematopoietic stem cells, which are adult stem cells that regenerate various types of blood cells throughout a person’s lifespan; and satellite cell modulation platform focuses on the in vivo pharmacologic activation of satellite stem cells that are adult stem cells that regenerate muscle throughout a person’s lifespan. The company’s lead product candidate includes ProHema, a pharmacologically-modulated HSC therapeutic derived from umbilical cord blood that is in Phase II clinical development for hematologic malignancies. It is developing pharmacologically optimized HSC therapeutics for the treatment of lysosomal storage disorders within the central nervous system; and Wnt7a Analogs that is in preclinical studies for regeneration in muscular dystrophies. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.

Company Website
Previous Close: 
4.12
Open: 
4.12
Bid: 
3.56
Ask: 
4.80
1yr Target Price: 
7.67
Day's Range: 
3.99 - 4.29
52wk Range: 
1.80 - 5.68
Volume: 
328156
Average Daily Volume: 
286267
Market Capitalization: 
175.19M
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
41415000M
content_right

Pages